当适当的抗血小板治疗未能预防支架血栓形成时,应该怎么做? 两个案例报告报告
Sungman Hong1, Jaegyok Song1, Sung Mi Ji1
1Department of Anesthesiology and Pain Medicine Dankook University College of Medicine Cheonan Republic of Korea.
Clinical case reports
|June 29, 2023
概括
麻醉科医生必须预测PCI后进行非心脏手术的高风险患者的静脉栓塞. 当标准方法失败时,静脉-体外膜氧化 (VA-ECMO) 提供了一个有前途的治疗方法.
科学领域:
- 心脏病学 心脏病学
- 麻醉学 麻醉学
- 心血管外科心血管外科
背景情况:
- 接受非心脏手术的穿皮冠状动脉干预 (PCI) 患者面临风险.
- 静脉栓塞是这些高风险个体中可能发生的关键并发症.
研究的目的:
- 突出在接受非心脏手术的患者中管理静脉栓塞的挑战.
- 将VA-ECMO作为耐火病例的潜在治疗选择.
主要方法:
- 对涉及PCI的高风险手术患者的临床情景的审查.
- 讨论用于静脉栓塞的治疗算法.
- 评估VA-ECMO作为一个救援疗法.
主要成果:
- 静脉栓塞可以耐常规治疗和心肺复苏.
- 在危急情况下,VA-ECMO显示出作为有效的救援疗法的潜力.
结论:
- 在非心脏手术期间,麻醉科医生必须对高风险PCI患者的静脉栓塞保持警.
- VA-ECMO代表了一种有价值的治疗选择,用于管理对标准干预不反应的危及生命的静脉栓塞.
相关概念视频
Peripheral Artery Disease III: Interprofessional Care
11
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
11
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
566
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
566
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Atherosclerosis III: Management
13
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
13
Coronary Artery Disease V: Interprofessional Care
10
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
10
Angina IV: Management
11
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
11


